Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study

作者全名：Qin, Yalan; Hao, Lingfang; Liu, Xisong; Liang, Run; Zhang, Junjing; Zhang, An

作者地址：[Qin, Yalan; Zhang, An] Chongqing Med Univ, Dept Crit Care Med, Affiliated Hosp 2, 76 Linjiang Rd, Chongqing 400016, Peoples R China; [Hao, Lingfang; Liang, Run] Hohhot First Hosp, Dept Oncol, Hohhot 010030, Peoples R China; [Liu, Xisong] Chongqing Publ Hlth Treatment Ctr, Dept Crit Care Med, Chongqing 400030, Peoples R China; [Zhang, Junjing] Hohhot First Hosp, Dept Hepatobiliary Surg, 150 South Second Ring Rd, Hohhot 010030, Inner Mongolia, Peoples R China

通信作者：Zhang, A (通讯作者)，Chongqing Med Univ, Dept Crit Care Med, Affiliated Hosp 2, 76 Linjiang Rd, Chongqing 400016, Peoples R China.; Zhang, JJ (通讯作者)，Hohhot First Hosp, Dept Hepatobiliary Surg, 150 South Second Ring Rd, Hohhot 010030, Inner Mongolia, Peoples R China.

来源：BMC PHARMACOLOGY & TOXICOLOGY

ESI学科分类：PHARMACOLOGY & TOXICOLOGY

WOS号：WOS:001205741100001

JCR分区：Q2

影响因子：2.8

年份：2024

卷号：25

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：COVID-19; BRII-196; BRII-198; Neutralizing antibody therapy; Therapeutic effect

摘要：Background Monoclonal antibody therapy for Covid-19 springs up all over the world and get some efficiency. This research aims to explore the treating effect of BRII-196(Ambavirumab) plus BRII-198(Lomisivir) on Covid-19. Methods In this retrospective cohort research, patients received standard care or plus BRII-196 /BRII-198 monoclonal antibodies. General comparison of clinical indexes and prognosis between Antibody Group and Control Group was made. Further, according to the antibody using time and patients' condition, subgroups included Early antibody group, Late antibody group, Mild Antibody Group, Mild Control Group, Severe Antibody Group and Severe Control Group. Results Length of stay(LOS) and interval of Covid-19 nucleic acid from positive to negative of Antibody Group were 12.0(IQR 9.0-15.0) and 14.0(IQR 10.0-16.0) days, less than those(13.0 (IQR 11.0-18.0) and 15.0 (IQR 12.8-17.0) days) of Control Group(p = 0.004, p = 0.004). LOS(median 10days) of Early Antibody Group was the shortest, significantly shorter than that of Control Group (median 13days)(p < 0.001). Interval(median 12days) of Covid-19 nucleic acid from positive to negative of Early Antibody Group also was significantly shorter than that of Control Group(median 15days) and Late Antibody Group(median 14days)(p = 0.001, p = 0.042). LOS(median 12days) and interval(median 13days) of Covid-19 nucleic acid from positive to negative of Mild Antibody Group was shorter than that of Mild Control Group(median 13days; median 14.5days)(p = 0.018, p = 0.033). Conclusion The neutralizing antibody therapy, BRII-196 plus BRII-198 could shorten LOS and interval of Covid-19 nucleic acid from positive to negative. However, it didn't show efficacy for improving clinical outcomes among severe or critical cases.

基金机构：Chongqing Special Research Project for Novel Coronavirus Pneumonia Prevention and Control

基金资助正文：The authors appreciate Yu Wei, PhD, from Chongqing Medical University, for revising and drawing the figures.